Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease

INTRODUCTION: Recent failures in phase 3 clinical trials in Alzheimer's disease (AD) suggest that novel approaches to drug development are urgently needed. Phase 3 risk can be mitigated by ensuring that clinical efficacy is established before initiating confirmatory trials, but traditional phas...

Descripción completa

Detalles Bibliográficos
Autores principales: Satlin, Andrew, Wang, Jinping, Logovinsky, Veronika, Berry, Scott, Swanson, Chad, Dhadda, Shobha, Berry, Donald A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Featured Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644271/
https://www.ncbi.nlm.nih.gov/pubmed/29067290
http://dx.doi.org/10.1016/j.trci.2016.01.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5644271/
https://www.ncbi.nlm.nih.gov/pubmed/29067290
http://dx.doi.org/10.1016/j.trci.2016.01.001

Ejemplares similares